Ospedale Fatebenefratelli Isola Tiberina Gemelli Isola
- Address
- lock Available on a paid plan
Gastroenterology and Inflammatory Bowel Disease
At Ospedale Fatebenefratelli Isola Tiberina Gemelli Isola in Rome, clinical research in digestive system diseases focuses on ulcerative colitis, Crohn's disease, and other inflammatory conditions affecting the gut. These studies are designed to test new treatments and better understand how to achieve and maintain remission in chronic intestinal disease.
- Testing novel therapies for ulcerative colitis
- Evaluating treatment options for Crohn's disease
- Studying approaches to improve clinical remission and long-term disease control
The site also explores related gastrointestinal conditions such as eosinophilic gastritis, reflecting a broader interest in improving care for patients with difficult-to-treat digestive disorders.
Oncology and Precision Cancer Care
Research in neoplasms is a major focus, with trials covering breast cancer, colorectal cancer, lung cancer, melanoma, and head and neck cancer. Many of these studies aim to improve how cancers are treated after surgery, in advanced disease, or when standard options are no longer effective.
- Evaluating new treatment strategies for advanced solid tumors
- Studying therapies for breast cancer and triple-negative breast cancer
- Assessing options for colorectal cancer and metastatic disease
- Testing treatment effectiveness in non-small cell lung cancer, small cell lung cancer, and melanoma
These trials are largely focused on improving survival, controlling disease progression, and identifying more effective personalized cancer treatments.
Neurology and Alzheimer’s Disease
The site supports clinical trials in nervous system diseases, especially Alzheimer's disease and early symptomatic Alzheimer’s disease. This research is aimed at understanding whether new therapies can slow cognitive decline and support patients in the earliest stages of memory loss and dementia.
- Testing potential treatments for early Alzheimer’s disease
- Evaluating safety and long-term tolerability of new neurological therapies
- Studying whether treatment can slow clinical progression and preserve function
These studies reflect a strong interest in finding better ways to diagnose and manage progressive brain disorders before they advance further.
Cardiovascular and Metabolic Research
Clinical trials in cardiovascular diseases, nutritional and metabolic diseases, and related metabolism and immune system phenomena include studies in type 2 diabetes, acute myocardial infarction, heart failure due to ATTR amyloidosis, chronic kidney disease, and broader cardiometabolic risk reduction. The goal is to improve outcomes in patients with common and high-risk chronic illnesses.
- Testing therapies to reduce major adverse cardiovascular events
- Studying treatment effects in type 2 diabetes and cardiovascular autonomic neuropathy
- Evaluating options for chronic kidney disease progression
- Exploring new care strategies for ATTR amyloid cardiomyopathy
Research here often connects heart, kidney, and metabolic health, showing a broad interest in preventing complications across multiple organ systems.
Respiratory, Skin, and Ophthalmology Studies
Additional work spans respiratory tract diseases, skin and connective tissue diseases, and eye diseases. These trials involve conditions such as asthma, chronic spontaneous urticaria, and neovascular age-related macular degeneration, with a focus on improving symptom control and quality of life.
- Assessing new treatments for asthma
- Studying therapies for chronic spontaneous urticaria
- Evaluating approaches for neovascular age-related macular degeneration
- Supporting research into immune-related skin and allergy conditions
These studies broaden the research portfolio at the Rome site by addressing chronic conditions that affect breathing, skin health, and vision.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 13 therapeutic areas and 15 of 98 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 86 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 22 by active trials.
- 1Pfizer Inc.4active
lock +21 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Pfizer Inc.5trials
lock +6 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Ospedale Fatebenefratelli Isola Tiberina Gemelli Isola
lock Showing 1 of 42 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A 52-week, randomised, double blind, multicentre, 2-arm parallel group trial assessing the efficacy and safety of CHF6001 (total daily dose 3200 μg) Dry Powder Inhaler (DPI) add-on to maintenance medium or high dose inhaled corticosteroid in combination with long-acting ß2-agonists in subjects with uncontrolled asthma | Chiesi Farmaceutici S.p.A. | Phase II | Not Recruiting | Nov 2023 | Dec 2025 |
IMP list
lock Showing 1 of 98 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Carboplatin | 4 | Unknown | 2018-07-31 | 2026-06-01 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.
